Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

(2021) Annette B. Vogel et al.   NATURE

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

(2021) Susanne Rauch et al.   npj Vaccines

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

(2020) Vincent J. Munster et al.   NATURE

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

(2020) Noe B. Mercado et al.   NATURE

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

(2020) Neeltje van Doremalen et al.   NATURE

Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults

(2020) Mark J. Mulligan et al.   NATURE

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

(2020) Kizzmekia S. Corbett et al.   NEW ENGLAND JOURNAL OF MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

(2020) Simon P. Graham et al.   npj Vaccines

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

(2020) Amin Addetia et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET

Animal models for COVID-19

(2020) César Muñoz-Fontela et al.   NATURE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlates of protection against SARS-CoV-2 in rhesus macaques

(2020) Katherine McMahan et al.   NATURE

Advances in RNA Vaccines for Preventive Indications: A Case Study of A Vaccine Against Rabies

(2019) Armbruster et al.   Vaccines

New Vaccine Technologies to Combat Outbreak Situations

(2018) Susanne Rauch et al.   Frontiers in Immunology

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

(2017) Johannes Lutz et al.   npj Vaccines

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

(2016) Margit Schnee et al.   PLoS Neglected Tropical Diseases

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

(2012) Benjamin Petsch et al.   NATURE BIOTECHNOLOGY

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

(2010) Mariola Fotin-Mleczek et al.   JOURNAL OF IMMUNOTHERAPY